FDA VRBPAC Meetings

*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.

May 18, 2023

FDA VRBPAC Meeting | May 18th, 2023

Read Chat Transcript

Agenda The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On May 18, 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.

Liveblog provided by Meryl Nass, MD.

Available in these languages:

    English language selector
    Spanish language selector
    German language selector
    French language selector
    Italian language selector
    Portuguese language selector

Children's Health Defense® is a 501(c)(3) non-profit organization. Our mission is to end childhood health epidemics by working aggressively to eliminate harmful exposures, hold those responsible accountable and establish safeguards to prevent future harm. We fight corruption, mass surveillance and censorship that put profits before people as well as advocate for worldwide rights to health freedom and bodily autonomy.

    English language selector
    Spanish language selector
    German language selector
    French language selector
    Italian language selector
    Portuguese language selector
SUBSCRIBE - IT'S FREE!BECOME A MEMBER
Twitter Social Media iconTelegram Social Media IconGettr IconGab IconRumble Social Media IconBitchute Social Media IconReddit IconOdysee IconSovren IconTruth Social Icon

Donations are tax deductible to the full extent of the law. EIN #26-0388604

© 2016 - 2023 Children's Health Defense® • All Rights Reserved